Our results demonstrated that nuclear translocation of β-catenin is significantly reduced upon EPBS treatment, suggesting that it may be implemented alongside EGFR tyrosine kinase inhibitors in drug-resistant cancers. The gene discussed is EGFR; the disease is cancer.